Anti-CD20 Antibody Pipeline: 20+ Trailblazing Companies Powering the Future of Targeted Therapies | DelveInsight

The anti-CD20 antibody market is entering a new era of innovation, driven by over 20 leading biotech and pharma players, including Bioxpress Therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, and BioThera Solutions. These visionaries are reshaping treatment paradigms with next-gen therapies that promise greater precision and better outcomes.

DelveInsight's "Anti-CD20 Antibody Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Anti-CD20 Antibody market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging anti-CD20 antibody drugs, the anti-CD20 antibody pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Anti-CD20 Antibody Pipeline Report
• DelveInsight's anti-CD20 antibody Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline drugs for anti-CD20 antibody treatment.
• The leading anti-CD20 antibody companies include TG Therapeutics, Roche, Genmab/Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencor, KindredBio, Boehringer Ingelheim, Bioxpress Therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera Solutions, and others are evaluating their lead assets to improve the Anti-CD20 Antibody treatment landscape.
• Key anti-CD20 antibody pipeline therapies in various stages of development include Ublituximab, Obinutuzumab, Ofatumumab, Glofitamab, Research programme: anti-CD20 monoclonal antibodies, Epcoritamab, Odronextamab, IGM-2323, BI 695500, Mosunetuzumab, AME-133v, XmAb13676, BXT 2336, 304, Ripertamab, DI Leu16 IL2, PF-05280586, Rituximab, BAT4306F, and others.
• In March 2025, Roche announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for GAZYVA®/GAZYVARO® (obinutuzumab) for treating lupus nephritis. The acceptance is based on positive Phase III REGENCY study results, which showed improved complete renal response when Gazyva was added to standard therapy.
• In February 2025, Regeneron announced that the FDA accepted the resubmitted Biologics License Application (BLA) for odronextamab to treat relapsed/refractory follicular lymphoma (FL) after two or more prior therapies. The FDA's target decision date is July 30, 2025.
• In March 2024, BeiGene announced that the FDA granted accelerated approval to BRUKINSA® (zanubrutinib), in combination with obinutuzumab, for treating adults with relapsed or refractory follicular lymphoma (FL) after two or more prior therapies.
• In August 2024, Indapta Therapeutics announced that the FDA cleared the IND for its Phase 1 trial of IDP-023, a g-natural killer (g-NK) cell therapy, for the treatment of progressive multiple sclerosis (MS).

Request a sample and discover the recent breakthroughs happening in the anti-CD20 antibody pipeline landscape @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Anti-CD20 Antibody Overview
CD20 is a non-glycosylated phosphoprotein, weighing 33-37 kDa, found on the surface of mature, undifferentiated B cells. Its expression begins at the pre-B-cell stage and continues until the cell differentiates into a plasma cell. Due to its consistent and high-level expression on malignant B cells, CD20 has become a key therapeutic target. Structurally, CD20 includes four hydrophobic transmembrane domains, one intracellular domain, and two extracellular loops (one large and one small), with both the N- and C-termini located within the cytoplasm.

The widespread presence of CD20 on transformed B cells underlies the development of anti-CD20 monoclonal antibodies (mAbs), which are used to deplete B cells. Initially designed to treat B cell malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), anti-CD20 therapies are now widely used for conditions characterized by high CD20 expression. These antibodies rank among the most effective therapies in both oncology and immune-related disorders.

Find out more about anti-CD20 antibody medication @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Anti-CD20 Antibody Treatment Analysis: Drug Profile
Ublituximab: TG Therapeutics
Ublituximab (TG-1101) is an investigational, glycoengineered anti-CD20 monoclonal antibody that targets a unique epitope on CD20-positive B cells. Upon binding, it initiates immune responses such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell destruction. TG Therapeutics has completed a rolling Biologics License Application (BLA) submission to the FDA for ublituximab as a treatment for chronic lymphocytic leukemia (CLL). The FDA has granted Fast Track designation to the ublituximab-umbralisib (U2) combination and Orphan Drug status for the same indication.

Glofitamab: Roche
Glofitamab (RO7082859, RG6026) is an investigational bispecific antibody that targets both CD20 on malignant B cells and CD3 on T cells, redirecting T cells to attack cancerous B cells. It is currently being evaluated in a Phase III trial comparing glofitamab + gemcitabine + oxaliplatin to rituximab + gemcitabine + oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Key Anti-CD20 Antibody Therapies and Companies
• Ublituximab: TG therapeutics
• Glofitamab: Roche

Learn more about the novel and emerging anti-CD20 antibody pipeline therapies @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Anti-CD20 Antibody Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Anti-CD20 Antibody Pipeline Report
• Coverage: Global
• Key Anti-CD20 Antibody Companies: TG Therapeutics, Roche, Genmab/Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencor, KindredBio, Boehringer Ingelheim, Bioxpress Therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera Solutions, and others.
• Key Anti-CD20 Antibody Pipeline Therapies: Ublituximab, Obinutuzumab, Ofatumumab, Glofitamab, Research programme: anti-CD20 monoclonal antibodies, Epcoritamab, Odronextamab, IGM-2323, BI 695500, Mosunetuzumab, AME-133v, XmAb13676, BXT 2336, 304, Ripertamab, DI Leu16 IL2, PF-05280586, Rituximab, BAT4306F, and others.

Dive deep into rich insights for drugs used for anti-CD20 antibody treatment; visit @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Anti-CD20 Antibody Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Anti-CD20 Antibody Pipeline Therapeutics
6. Anti-CD20 Antibody Pipeline: Late-Stage Products (Phase III)
7. Anti-CD20 Antibody Pipeline: Late-Stage Products (Phase III)
8. Anti-CD20 Antibody Pipeline: Mid-Stage Products (Phase II)
9. Anti-CD20 Antibody Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.